Nicotinamide Riboside Results Timeline: What Studies Measured, and When
Published nicotinamide riboside trials measured outcomes at fixed timepoints rather than tracking week-by-week experience. Blood NAD+ metabolite changes were measured within hours of single oral doses, muscle NAD+ and inflammatory markers after 21 days, safety endpoints at four weeks, metabolic and body-composition endpoints at six weeks, and walking distance at six months in a peripheral artery disease trial. Reviews described the overall human evidence base as limited and heterogeneous, so these timepoints describe study design, not expected individual outcomes.
What a "results timeline" means in the nicotinamide riboside literature
Published trials of nicotinamide riboside (NR) did not follow participants for week-by-week impressions. They measured pre-specified biochemical, functional or safety outcomes at fixed timepoints and compared groups at those points. A timeline page, therefore, can only describe what was measured and when — not what any individual would experience. This page is for educational purposes only and is not medical advice; consult a licensed physician about any question regarding supplements, health conditions or treatment.
For general background on the molecule, its chemistry and its place in NAD+ metabolism, see the nicotinamide riboside overview. Below, human studies are grouped by the duration of the measurement window, from hours to months, with preclinical work labelled separately.
Hours after a single dose: pharmacokinetic timepoints
The shortest published timeline is pharmacokinetic. A 2016 Nature Communications report described NR as orally bioavailable in mice and humans and found that single oral doses of 100 mg, 300 mg and 1000 mg raised the blood NAD+ metabolome in a dose-dependent manner, with blood sampled across the hours following ingestion (PMID 27721479). That study establishes that measurable blood NAD+ metabolite changes occurred on a same-day scale; it does not report symptomatic, functional or clinical outcomes at that timepoint (PMID 27721479).
About three weeks: muscle NAD+ metabolome and inflammatory markers
One of the more frequently cited short-duration trials administered 1 g per day of NR for 21 days to aged men and reported that the aged human skeletal muscle NAD+ metabolome was augmented, alongside transcriptomic and anti-inflammatory signatures, with reductions in several circulating inflammatory cytokines measured at the end of the period (PMID 31412242). Researchers in that study sampled muscle tissue and blood at baseline and after the 21-day window, so the design speaks to three-week tissue biochemistry rather than to longer-term function (PMID 31412242).
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeFour weeks: high-dose safety endpoints
The NR-SAFE trial was a randomized, double-blind safety study of high-dose nicotinamide riboside — 3000 mg per day — in people with Parkinson's disease, with safety and tolerability assessed over four weeks (PMID 38016950). Its primary focus was adverse-event reporting and laboratory monitoring across that one-month window rather than symptom change, which is why the study is useful for timing questions about tolerability but not about efficacy (PMID 38016950).
Six weeks: metabolic and body-composition endpoints
A trial in healthy obese humans supplemented 1000 mg per day of NR for six weeks and reported alterations in body composition and in skeletal muscle acetylcarnitine concentrations measured at the end of that period (PMID 32320006). The study's endpoints were chosen in advance and assessed at the six-week mark, which illustrates a common design choice in NR research: a single post-treatment measurement rather than serial weekly tracking (PMID 32320006).
Crossover designs in chronic kidney disease
A randomized crossover clinical trial compared coenzyme Q10 and nicotinamide riboside in chronic kidney disease, with outcomes assessed at the end of each supplementation period and participants serving as their own controls (PMID 37159264). Crossover designs compress the timeline question further, because each measurement reflects a defined treatment block rather than continuous exposure (PMID 37159264).
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appCognitive endpoints in older adults
A randomized placebo-controlled trial enrolled older adults with mild cognitive impairment and compared nicotinamide riboside against placebo, with cognitive and biochemical outcomes assessed at the trial's pre-specified endpoint (PMID 37994989). Cognitive outcome measures typically require longer observation windows than blood NAD+ measures, and the study was designed accordingly rather than around early or interim impressions (PMID 37994989).
Six months: a functional endpoint in peripheral artery disease
The NICE randomized clinical trial studied nicotinamide riboside in peripheral artery disease and measured six-minute walking distance as its functional endpoint after six months of supplementation (PMID 38871717). This is among the longest randomized timelines in the published NR literature, and the report described results for the randomized population as well as analyses accounting for adherence (PMID 38871717).
Want the full course? Every compound, evidence-graded and cited, inside PeptideU.
Start learning freeLong-term observation: ataxia telangiectasia
A 2024 report in Movement Disorders described long-term nicotinamide riboside use in ataxia telangiectasia and reported improvements in coordination and eye movements over an extended observation period (PMID 37899683). Because that work concerned a rare genetic disorder with disease-specific outcome measures, researchers framed it within that clinical context rather than as a general timeline for healthy adults (PMID 37899683).
Timeline table: measurement windows in the cited human studies
| Measurement window | Population studied | What was measured | Citation |
|---|---|---|---|
| Hours after a single dose | Mice and humans | Blood NAD+ metabolome after 100, 300 or 1000 mg | PMID 27721479 |
| 21 days | Aged men | Muscle NAD+ metabolome, transcriptomic and anti-inflammatory signatures at 1 g/day | PMID 31412242 |
| 4 weeks | Parkinson's disease | Safety and tolerability of 3000 mg/day | PMID 38016950 |
| 6 weeks | Healthy obese adults | Body composition and muscle acetylcarnitine at 1000 mg/day | PMID 32320006 |
| Per crossover period | Chronic kidney disease | Outcomes after each supplementation block | PMID 37159264 |
| Trial endpoint | Older adults with mild cognitive impairment | Randomized, placebo-controlled outcome assessment | PMID 37994989 |
| 6 months | Peripheral artery disease | Six-minute walking distance | PMID 38871717 |
| Long-term use | Ataxia telangiectasia | Coordination and eye movements | PMID 37899683 |
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freePreclinical and mechanistic timelines, clearly labelled
Some of the most detailed NAD+ timelines come from laboratory work that does not map onto human weeks at all. The same 2016 report that described human pharmacokinetics also characterised oral bioavailability in mice, where tissue NAD+ metabolite changes were tracked in a controlled experimental setting (PMID 27721479).
Mechanistic work has also examined NAD+ biology in specific disease contexts. A 2025 paper in Skeletal Muscle reported NAD+ dyshomeostasis in RYR1-related myopathies, framing NAD+ metabolism as a pathway of interest in that condition rather than reporting a supplementation timeline (PMID 40846977). In oncology models, researchers reported that niacin restriction combined with NAMPT inhibition was synthetic lethal to neuroendocrine carcinoma, a finding about NAD+ precursor availability in tumour biology rather than about supplementation outcomes in people (PMID 38092728). Both are preclinical or mechanistic in scope and were not designed to answer how quickly anything changes in a supplement user.
Why published timepoints do not translate into individual expectations
Two reviews addressed this gap directly. A 2023 Science Advances analysis examined what is really known about the effects of nicotinamide riboside supplementation in humans and emphasised how limited and heterogeneous the randomized evidence remains (PMID 37478182). A 2023 review in The Journals of Gerontology surveyed dietary supplementation with NAD+-boosting compounds in humans and described current knowledge alongside future research directions, again noting variation in populations, doses and durations across trials (PMID 37068054).
Several structural features explain why a single "week-by-week" answer is not available from this literature:
- Different populations. Trials enrolled aged men (PMID 31412242), people with Parkinson's disease (PMID 38016950), and adults with peripheral artery disease (PMID 38871717), and those groups are not interchangeable.
- Different endpoints. Blood NAD+ metabolites, muscle biochemistry, body composition and walking distance operate on different biological timescales, as the six-week and six-month designs illustrate (PMID 32320006, PMID 38871717).
- Few measurements in between. Most trials compared baseline with a single endpoint, so intermediate weeks were often not characterised at all (PMID 37478182).
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appAdverse Events Across Timepoints: What Studies Report
Safety reporting also follows the timeline of each protocol. The NR-SAFE trial specifically tested high-dose nicotinamide riboside at 3000 mg per day over four weeks in Parkinson's disease and was designed around safety and tolerability monitoring across that window (PMID 38016950). Longer trials collected adverse events over their own durations, including the six-month peripheral artery disease study (PMID 38871717) and the crossover study in chronic kidney disease (PMID 37159264). Reviews of NAD+-boosting compounds in humans have noted that safety characterisation beyond these relatively short and modestly sized trials remains an open research question (PMID 37068054).
What the literature has not established about timing
No published trial in this citation set tracked subjective energy, sleep or wellbeing week by week, and none established a threshold at which a specific outcome "appears". The 2023 Science Advances review argued that claims about human effects frequently outrun the randomized evidence available (PMID 37478182). What can be said with citation support is narrower: blood NAD+ metabolite changes were measurable within hours of single oral doses (PMID 27721479), muscle NAD+ and inflammatory signatures were measured after 21 days of 1 g per day (PMID 31412242), and functional endpoints such as six-minute walking distance were assessed only after months (PMID 38871717). Readers comparing these timelines should treat them as descriptions of study protocols, not as forecasts.
Want the full course? Every compound, evidence-graded and cited, inside PeptideU.
Start learning freeReferences
- Nicotinamide riboside is uniquely and orally bioavailable in mice and humans (Nature Communications, 2016)
- Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD(+) Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures (Cell Reports, 2019)
- Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans (The American Journal of Clinical Nutrition, 2020)
- Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions (The Journals of Gerontology: Series A, 2023)
- Randomized crossover clinical trial of coenzyme Q10 and nicotinamide riboside in chronic kidney disease (JCI Insight, 2023)
- What is really known about the effects of nicotinamide riboside supplementation in humans (Science Advances, 2023)
- NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease (Nature Communications, 2023)
- Niacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma (Nature Communications, 2023)
- Long-Term Nicotinamide Riboside Use Improves Coordination and Eye Movements in Ataxia Telangiectasia (Movement Disorders, 2024)
- A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment (GeroScience, 2024)
- Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial (Nature Communications, 2024)
- NAD(+) dyshomeostasis in RYR1-related myopathies (Skeletal Muscle, 2025)
Frequently asked questions
What is the shortest timepoint at which studies measured any nicotinamide riboside effect?▾
Pharmacokinetic sampling was the earliest. A 2016 study reported that single oral doses of 100, 300 and 1000 mg increased the blood NAD+ metabolome in a dose-dependent manner in humans, with measurements taken over the hours following ingestion (PMID 27721479). Those were biochemical measurements in blood, not functional or symptomatic outcomes at that timepoint.
Did any trial measure outcomes at around three weeks?▾
Yes. Researchers administered 1 g per day for 21 days to aged men and reported that the skeletal muscle NAD+ metabolome was augmented, with transcriptomic and anti-inflammatory signatures and reductions in several circulating inflammatory cytokines measured at the end of that period (PMID 31412242). Measurements were taken at baseline and after 21 days rather than weekly.
What did four-week and six-week trials assess?▾
A four-week randomized, double-blind trial evaluated the safety and tolerability of high-dose nicotinamide riboside at 3000 mg per day in Parkinson's disease (PMID 38016950). A separate six-week study in healthy obese humans reported changes in body composition and skeletal muscle acetylcarnitine concentrations at 1000 mg per day (PMID 32320006). The endpoints differed substantially between these designs.
Is there a long human trial with a functional endpoint?▾
The NICE randomized clinical trial studied nicotinamide riboside in peripheral artery disease and measured six-minute walking distance after six months of supplementation (PMID 38871717). Separately, a 2024 report described long-term use in ataxia telangiectasia and reported improvements in coordination and eye movements in that rare-disease population (PMID 37899683).
Why do reviews describe the human evidence as limited?▾
A 2023 Science Advances review examined what is really known about nicotinamide riboside supplementation in humans and emphasised the limited, heterogeneous randomized evidence (PMID 37478182). A 2023 review of NAD+-boosting compounds in humans similarly described current knowledge and future research directions, noting variation in populations, doses and durations across trials (PMID 37068054).
Do preclinical studies provide a usable timeline?▾
Preclinical work addresses mechanism rather than supplementation timing in people. A 2025 paper reported NAD+ dyshomeostasis in RYR1-related myopathies (PMID 40846977), and a 2023 study reported that niacin restriction with NAMPT inhibition was synthetic lethal to neuroendocrine carcinoma (PMID 38092728). Neither was designed to describe when a supplement effect appears in humans.
Did any study track week-by-week changes in how participants felt?▾
No trial in this citation set reported serial weekly subjective tracking. Most compared baseline with a single pre-specified endpoint, such as the crossover design in chronic kidney disease that assessed outcomes at the end of each supplementation period (PMID 37159264), or the randomized placebo-controlled trial in older adults with mild cognitive impairment (PMID 37994989).
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.